- 19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries
- Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine
- Out-licenses its patented technology to third party partners, with several deals signed or pending
When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way: bioavailability matters. The company realized that if hemp oil ingredients were infused within lipids found in popular foods, the common problems of bad taste, poor absorption in the body and lack of product variety could be solved.
Lexaria has since developed a superior method of lipid-delivery technology through a patented process that does this by infusing the beneficial elements of hemp oil to lipid molecules. Lexaria reminds consumers that it is not mixing hemp oil into a product; it is infusing organically sourced, high purity hemp oil inside the molecules of other ingredients to produce superior tasting and performing food and beverages, including premium teas, protein energy bars and hemp oil capsules formulated with ginseng and ginkgo for enhanced memory and focus.
Additionally, this technologically superior method of delivery is being considered for other products in demand by consumers, namely nicotine-based products. Lexaria’s method could remove many of the dangerous side effects of nicotine, although the patented molecular delivery technology for this product remains in its early stages (http://dtn.fm/c2VCP).
Lexaria is also seeking patents to use its lipophilic enhancement technology for tetrahydrocannabinol (THC) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), nicotine and other molecules. New business-to-business relationships are on the horizon in the fields of vitamins, NSAIDs and nicotine delivery.
For more information, visit the company’s website www.LexariaEnergy.com
Let us hear your thoughts: Lexaria Bioscience Corp. Message Board
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.